Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared on X about a recent paper by Federica Lo Prinzi et al. published in Springer Nature:
“A real-world comparative effectiveness study of Atezolizumab + Bevacizumab vs. Tremelimumab + Durvalumab (STRIDE) in advanced hepatocellular carcinoma (HCC).
No significant OS difference overall
Female patients showed better outcomes with Atezo/Beva (HR 1.77, p=0.04)Insightful data from >2,300 patients using the TriNetX network.
A must-read for HCC treatment decision-making.”
Title: Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
Authors: Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Camera, Silvia Foti, Mara Persano, Francesco Vitiello, Emanuela Di Giacomo, Mariam Grazia Polito, Margherita Rimini and Andrea Casadei-Gardini
Other posts featuring Galip Can Uyar.
